A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

Robert Uger Biography and Net Worth

Insider of Trillium Therapeutics

Dr. Uger has spent the past 18 years developing novel agents targeting the immune system. He began his industry career in cancer vaccine research with Aventis Pasteur, and then joined start-up Trillium Therapeutics (private company) as Director, Research & Development, later serving as Vice President, R & D. At Trillium, Dr. Uger has overseen the growth of the company’s pipeline and guided several compounds from concept to the clinic. His expertise spans both innate and adaptive immunology, and he has overseen programs in the fields of immuno-oncology, autoimmunity and transplantation. He received his Ph.D. in immunology from the University of Toronto.

What is Robert Uger's net worth?: The estimated net worth of Robert Uger is at least $67,232.24 as of July 7th, 2021. Dr. Uger owns 3,646 shares of Trillium Therapeutics stock worth more than $67,232 as of April 23rd. This net worth approximation does not reflect any other assets that Dr. Uger may own. Learn More about Robert Uger's net worth.
How do I contact Robert Uger?: The corporate mailing address for Dr. Uger and other Trillium Therapeutics executives is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. Trillium Therapeutics can also be reached via phone at (416) 595-0627 and via email at [email protected]. Learn More on Robert Uger's contact information.
Has Robert Uger been buying or selling shares of Trillium Therapeutics?: Robert Uger has not been actively trading shares of Trillium Therapeutics during the last quarter. Most recently, Robert Uger sold 3,646 shares of the business's stock in a transaction on Wednesday, July 7th. The shares were sold at an average price of $9.00, for a transaction totalling $32,814.00. Following the completion of the sale, the insider now directly owns 3,646 shares of the company's stock, valued at $32,814. Learn More on Robert Uger's trading history.

Robert Uger Insider Trading History at Trillium Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/7/2021	Sell	3,646	$9.00	$32,814.00	3,646
6/7/2021	Sell	3,646	$8.27	$30,152.42	3,646
5/7/2021	Sell	3,646	$9.30	$33,907.80	3,646
4/7/2021	Sell	3,646	$10.82	$39,449.72	3,646
3/8/2021	Sell	3,646	$10.11	$36,861.06	3,646
1/11/2021	Sell	584	$15.20	$8,876.80	584

Robert Uger Buying and Selling Activity at Trillium Therapeutics

Trillium Therapeutics Company Overview

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Today's Range

Now: $18.44

$18.44

50 Day Range

MA: $18.12

$17.50

$18.44

2 Week Range

Now: $18.44

$5.80

$20.96

Volume

8 shs

Average Volume

1,866,404 shs

Market Capitalization

$1.94 billion

P/E Ratio

29.74

Dividend Yield

N/A

Beta

2.08

Incredible Opportunity to Retire FAST!

From Crypto 101 Media | Ad